Intersections between the maternal microbiome, placental immunity, vasculature and fetal growth
Intersections between the maternal microbiome, placental immunity, vasculature and fetal growth
批准号:
10049188
负责人:
Geoffrey Nathan Pronovost
金额:
$4.01万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-11-01 至 2021-10-31
关键词:
AntibioticsBindingBiochemicalBiological AvailabilityBloodBlood VesselsCell physiologyCellsChildDataDeveloping CountriesDevelopmentDietDietary intakeEffector CellEndothelial CellsEnsureEnvironmental ExposureEnvironmental Risk FactorExperimental DesignsFetal DevelopmentFetal GrowthFetal Growth RetardationFetal healthFetusFlow CytometryGene Expression ProfileGerm-FreeGnotobioticGrowthGrowth and Development functionHealthHigh PrevalenceHomeostasisImmuneImmune System DiseasesImmunityImpaired healthImpairmentInfectionInvestigationLightLiteratureMalnutritionMaternal HealthMediatingMissionModelingMusNational Institute of Child Health and Human DevelopmentNatural Killer CellsOrganPathogenesisPhenotypePhysiologyPlacentaPlacental InsufficiencyPregnancyPregnancy ComplicationsPrevalenceProcessProteinsRegulationReproductive ProcessResearchRisk FactorsRoleSignal TransductionSpiral Artery of the EndometriumStressStructureTechnical ExpertiseTestingTherapeuticTrainingUnited StatesUterusVascular Endothelial CellVascularizationWeightWomanWorld Health Organizationangiogenesisbaseclinically relevantconfocal imagingdysbiosisexperimental analysisfetalgut microbiomehealth care availabilityimmune activationimmune functionimmunoregulationimprovedin vitro Assayinsightmaternal microbiomematernal microbiotamicroCTmicrobialmicrobiomemicrobiome alterationmicrobiotamother nutritionnovelnovel strategiesnutritionperinatal outcomespre-doctoralsingle-cell RNA sequencingsocioeconomicstherapeutic targetwhole body imaging
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The World Health Organization identifies intrauterine growth restriction (IUGR) as a primary risk factor for
adverse perinatal outcomes and long-term health consequences. It afflicts an estimated 100,000 children born
each year in the United States, with even higher prevalence in developing countries and socioeconomic groups
with limited access to healthcare. IUGR is commonly associated with poor maternal nutrition and placental
insufficiencies, including immune dysfunction and impaired vascular growth, but how environmental factors
regulate these processes is not completely understood. The gut microbiome mediates environmental
contributions to host immune function and angiogenesis, and microbiota composition is markedly influenced by
dietary intake. This warrants investigation of the microbiome as a critical regulator of placental homeostasis,
opening the possibility for microbiota-based therapeutic strategies to treat IUGR. Indeed, this novel approach
to improve maternal health during gestation and treat IUGR aligns with the NICHD mission, specifically to
ensure “…that women suffer no harmful effects from reproductive processes, and that all children have the
chance to achieve their full potential for healthy and productive lives.”
My preliminary data supports the central hypothesis that dysbiosis of the maternal microbiome during
pregnancy impairs placental angiogenic immune cells and vasculature, leading to downstream abnormalities in
fetal development. Further, my data supports the presumption that the microbiome regulates circulating
metabolites that have known immunoregulatory and angiogenic potential that can act systemically throughout
the host. My rationale is that disrupting the maternal microbiome, whether through bacterial depletion or
through maternal nutrition, alters bioavailability of circulating biochemicals that are critical for maternal and fetal
health during pregnancy. I propose to test my central hypothesis with the following aims: Aim 1: Investigate
effects of the maternal microbiome on placental immune homeostasis; Aim 2: Examine how the maternal
microbiome regulates placental vascular development; Aim 3: Determine mechanistic influences of the
maternal microbiome on fetal growth. Upon completion, I will provide novel insights into how the maternal
microbiome regulates placental immune and vascular homeostasis through specific molecular interactions.
This mechanistic approach is significant because it sheds light on a causal role of the microbiome as a
regulator of IUGR, and opens the potential for microbiome-based therapeutic targets to markedly improve
maternal and fetal health on a global scale.
The proposed research is of critical importance for my predoctoral training, as I will develop and refine my
technical skills, experimental design and analysis, and critical review of scientific literature from multiple fields.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intersections between the maternal microbiome, placental immunity, vasculature and fetal growth
-
批准号:9911950
-
项目类别:
-
资助金额:$3.91万
-
财政年份:2019
-
负责人:Geoffrey Nathan Pronovost
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: